B
Bull
Bull · 25%TLSA
$1.98
Precio del escenario
$1.010
-0.065 (-6.48%)Al cierre
Loading chart…
- High
- 1.100
- Open
- 1.100
- VWAP
- 1.04
- Vol
- 566.41K
- Mkt Cap
- 89.33M
- Low
- 0.998
- Amount
- 586.81K
- EV/EBITDA, TTM
- 0.00
Tiziana Life Sciences Ltd. is a biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Its clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer’s, and Amyotrophic lateral sclerosis. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.
AI analysis of Tiziana Life Sciences Ltd (TLSA)
buyTiziana Life Sciences Ltd is a good buy right now due to the recent insider purchases, with CEO Ivor Elrifi buying 667,000 shares at $1 each, and the stock currently priced at $1.01. The RSI is at 30.017, indicating that the stock is oversold, and there is potential for recovery. However, the company has a high forward P/E ratio of 0, indicating uncertainty in future earnings, which is a risk.
Métricas de valoración
The current forward P/E ratio for Tiziana Life Sciences Ltd (TLSA) is 0.00, compared to its 5-year average forward P/E of -5.59.
Alphio AI Price Scenarios for TLSA
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
5.008-04seekingalphaTiziana CEO Ivor Elrifipurchases 667,000 Shares, Boosting Stake
9.007-31GlobenewswireTiziana Life Sciences Reports Clinical Trial Results for Foralumab
9.007-31NewsfilterTiziana Life Sciences Reports Progress on Foralumab Therapy
- 5.007-22seekingalpha
Tiziana Life Sciences Executive Chairman Increases Stake
- 9.006-25Newsfilter
Tiziana Life Sciences Initiates FORALUMAB Clinical Trial for MS
TLSA FAQ — answered by Alphio AI
Tiziana Life Sciences Ltd. is a biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Its clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer’s, and Amyotrophic lateral sclerosis. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer. It operates in the Healthcare sector.
Tiziana Life Sciences Ltd is a good buy right now due to the recent insider purchases, with CEO Ivor Elrifi buying 667,000 shares at $1 each, and the stock currently priced at $1.01. The RSI is at 30.017, indicating that the stock is oversold, and there is potential for recovery. However, the company has a high forward P/E ratio of 0, indicating uncertainty in future earnings, which is a risk.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.